Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study.
A clinical trial of an immunotherapy which consisted of intratumoural injections of autologous lymphocytes with human lymphoblastoid interferon was evaluated in 31 patients with intracranial glioblastoma. Immunotherapy was performed after stereotactic biopsy or surgical resection. The treatment was tolerated well by all patients. Three patients showed positive response to immunotherapy as documented by transient regression or stabilization of the tumour size on computed tomography. Nevertheless, there is no significant difference in the survival time of the patients treated with immunotherapy and those not treated. We conclude that this immunotherapeutic regimen is not beneficial in patients with glioblastoma when used as single treatment after tumoural biopsy or resection.
Vaquero
J
J
Department of Neurosurgery, Puerta de Hierro Clinic, Autonomous University, Madrid, Spain.
Martínez
R
R
Ramiro
J
J
Salazar
F G
FG
Barbolla
L
L
Regidor
C
C
D001932:Brain Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D015552:Injections, Intralesional; D007370:Interferon Type I / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*
D007370:Interferon Type I